Corporate Banner
Satellite Banner
ADME Tox
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Hepregen Announces Appointment of Dr. Michael Holsapple

Published: Wednesday, August 07, 2013
Last Updated: Wednesday, August 07, 2013
Bookmark and Share
Appointment adds respected leader in toxicology to Hepregen’s senior management team, reflecting ongoing commitment of Hepregen’s strategic investor, Battelle Memorial Institute.

Hepregen Corporation has announced the appointment of Dr. Michael P. Holsapple as Vice President of Toxicology Product Development.

This appointment of Dr. Holsapple, who will also retain his position at Battelle Memorial Institute (“Battelle”), was accomplished as a part of an investment and commercial development strategy co-elaborated by senior management at Hepregen and Battelle.

Following a successful 13-year academic career, Dr. Holsapple was leader of the Immunotoxicology and Respiratory Toxicology groups at Dow Chemical for eight years, after which, from 2002 to 2011, he served as the Executive Director of the Health and Environmental Sciences Institute (HESI), the global branch of the International Life Sciences Institute (ILSI) in Washington, DC.

He joined Battelle in 2011 as a Senior Leader Research in systems toxicology. Dr. Holsapple received the Society of Toxicology (SOT) Achievement Award in 1992.

In recognition of his contributions to immunotoxicology, he received the Vos Award: Career Achievement in Immunotoxicology in 2009.

Dr. Holsapple has served on Council for the SOT, and on Council for the American College of Toxicology (ACT). He was elected a ‘fellow’ in the Academy of Toxicological Sciences (ATS) in 2006, and a member of the Board of Trustees of the ATS in 2013. He is also a past President of the SOT.

Dr. Holsapple stated, “Hepregen has become the leader in next generation in vitro micro-liver products. Joining the Company’s outstanding team of scientists and commercially experienced senior managers is without a doubt an exceptional opportunity to participate in development of products that can transform the pharmaceutical, cosmetics and chemical industries.”

“Mike’s incredibly extensive scientific and organizational background in the field of toxicology provides Hepregen with an unmatched resource,” stated Dr. Vincent Zurawski, Hepregen’s chief executive officer, adding, “He brings a wealth of knowledge and experience to our emerging global enterprise.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

SOLVO Biotechnology and Hepregen Execute Co-Marketing Agreement
Agreement provides for European sales of Hepregen's HepatoPac® and HepatoMune™ proprietary products by SOLVO and provision of services using these products.
Wednesday, June 24, 2015
Scientific News
The Rise of 3D Cell Culture and in vitro Model Systems for Drug Discovery and Toxicology
An overview of the current technology and the challenges and benefits over 2D cell culture models plus some of the latest advances relating to human health research.
Alzheimer’s Protein Serves as Natural Antibiotic
Alzheimer's-associated amyloid plaques may be part of natural process to trap microbes, findings suggest new therapeutic strategies.
Vitamin A May Help Improve Pancreatic Cancer Chemotherapy
The addition of high doses of a form of vitamin A could help make chemotherapy more successful in treating pancreatic cancer, according to an early study by Queen Mary University of London (QMUL).
Breakthrough Approach to Breast Cancer Treatment
Scripps scientists have designed a drug candidate that decreases growth of breast cancer cells.
Non-Toxic Approach to Treating Variety of Cancers
A team of researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine recently discovered a novel, non-toxic approach to treating a wide variety of cancers.
Making Injectable Medicine Safer
Researchers remove excess additives from drugs, which could reduce the odds of serious allergic reactions and other side effects.
An Old-New Weapon Against Emerging Chikungunya Virus
Researchers utilize existing drugs to interfere with host factors required for replication of Chikungunya virus.
Brazilian Zika Virus Strain Causes Birth Defects in Experimental Models
First direct experimental proof of causal effect, researchers say.
'Kidney on a Chip' Facilitates Safer Drug Dosing
University of Michigan researchers have used a "kidney on a chip" device to mimic the flow of medication through human kidneys and measure its effect on kidney cells.
Ketamine Metabolism Lifts Depression
NIH-funded team finds rapid-acting, non-addicting agent in mouse study.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!